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Objectives:  Papillary  thyroid  microcarcinoma  (PTMC),  a tumor  that measures  1 cm or less,  according  to
World  Health  Organization  (WHO)  histological  classiﬁcation  of  tumors,  is  the  most  common  form  of
papillary  thyroid  carcinoma  (PTC)  comprising  much  more  than half  of all PTCs  if one  includes  the  so-
called  incidentalomas.  Although  PTMC has  an  excellent  prognosis,  a minority  of cases  were  found  to  be
clinically  aggressive.  We decided  to perform  a review  of  the  literature  on records  on PTMC  in attempt  to
ﬁnd  which  molecular  markers  might  be  used  as  predictors  of the clinical  behavior  of  PTMC.  This  review
article  aims to summarize  the  molecular  mechanisms  that  were  associated  to PTMCs  described  in  the  last
10 years,  with  a particular  focus  on  the  clinical  importance  of genetic  alterations  (BRAF  mutation,  RET/PTC
rearrangement,  NAD(P)H  and  NRH  polymorphisms  and  TERT  mutation)  and  anomalous  expression  of
several  molecules  (P53,  P27,  COX-2,  EGFR,  ki-67,  S100A4,  cyclin  D1,  galectin-3,  HMWK,  CK-19,  HBME-1,
HGF,  c-MET,  membrane  mucins  and  cell  adhesion  molecules).
Methods:  We  made  a  systematic  search  in the  PubMed  database  using  the  keywords  papillary  thyroid
microcarcinoma  and  reviewed  all the  articles  published  in  the  last  10 years,  in  English,  addressing  issues
related  to PTMC.
Results: Unfortunately,  all genetic  alterations  and  biomarkers  reported  to date  have  little  potential  per
se to  differentiate  between  indolent  and  aggressive  PTMCs.  Further  studies  using  the  aforementioned
markers  and,  most  likely,  others  are  needed  in  order  to  try  to ﬁnd  a  combination  of several  markers  that
may  be used  for increasing  the probability  of  identifying  PTMC  cases  with  more  aggressive  behavior,  thus
allowing  the  establishment  of  a more  appropriately  targeted  treatment.
© 2016  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
Espan˜a,  S.L.U.  This  is an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Biologia  molecular  dos  microcarcinomas  papilares  da  tiroide:  o  que  há
de  novo?
alavras-chave:
ancro da tiroide
icrocarcinoma papilar da tiroide
lterac¸ ões genéticas
r  e  s  u  m  o
Objetivos:  O  microcarcinoma  papilar  da tiroide,  um  tumor  que mede  1  cm  ou  menos,  de  acordo  com  a
classiﬁcac¸ ão histológica  dos tumores  da Organizac¸ ão  Mundial  da  Saúde,  é o  tipo  mais  comum  de car-
cinoma  papilar  da tiroide  e,  se incluirmos  os  chamados  incidentalomas,  corresponde  a muito mais  de
metade  de  todos  os  carcinomas  papilares  da  tiroide.  Embora  o  microcarcinoma  papilar  da  tiroide  tenha
um  excelente  prognóstico,  uma  minoria  dos casos  são  clinicamente  agressivos.  Decidimos  realizar  uma
revisão  da  literatura,  na  tentativa  de  encontrar  marcadores  moleculares  que  possam  ser utilizados  como
preditores  do comportamento  clínico  dos  microcarcinomas  papilares  da tiroide.  Este  artigo  de  revisão
pretende  resumir  os mecanismos  moleculares  que  foram  associados  ao  microcarcinoma  papilar  da  tiroide,
descritos  nos  últimos  10 anos,  com  um  particular  ênfase  na importância  clínica  das  alterac¸ ões  genéti-
cas  (mutac¸ ão  BRAF,  rearranjo  RET/PTC,  polimorﬁsmos  NAD[P]H  e NRH,  e mutac¸ ão  TERT)  e da  expressão
anormal  de  várias  moléculas  (P53,  P27, COX-2,  EGFR,  ki-67,  S100A4,  cyclin  D1,  Galectin-3,  HMWK,  CK-19,
HBME-1,  HGF,  c-MET,  mucinas  de  membrana  e moléculas  de  adesão  celular).
∗ Corresponding author.
E-mail address: mimed09002@med.up.pt (B. Castro).
http://dx.doi.org/10.1016/j.rpedm.2016.04.003
646-3439/©  2016  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND
icense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Métodos:  Foi  feita  uma  pesquisa  sistemática  na  base  de  dados  PubMed  usando  as palavras-chave  papillary
thyroid  microcarcinoma, com  subsequente  revisão  de  todos  os  artigos  relacionados  com  os  microcarcino-
mas papilares  da  tiroide  publicados  nos  últimos  10 anos,  em  inglês.
Resultados:  Infelizmente,  todas  as alterac¸ ões genéticas  e  biomarcadores  reportados  até  à data  têm,  per
se,  pouco  potencial  para  distinguir  entre  microcarcinomas  papilares  da  tiroide  indolentes  e agressivos.
Estudos  adicionais  utilizando  os  marcadores  acima  mencionados  e,  muito  provavelmente,  outros  são
necessários,  no  sentido  de  tentar  encontrar  uma  combinac¸ ão  de  vários  marcadores  que  possam  ser  uti-
lizados  para  aumentar  a probabilidade  de  identiﬁcar  os  casos  de  microcarcinoma  papilar  da  tiroide  com
um  comportamento  mais  agressivo,  permitindo  assim  estabelecer  um  tratamento  mais  apropriado  e
direcionado.
©  2016 Sociedade  Portuguesa  de Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
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Papillary thyroid microcarcinoma (PTMC) is deﬁned, by the
orld Health Organization (WHO), as a small papillary thyroid car-
inoma (PTC) measuring 10 mm or less in its greatest dimension.1
Thyroid cancer is the most frequent endocrine malignancy, rep-
esenting 2% of all malignant diseases and is responsible for almost
0% of neuroendocrine cancers.2,3 Eighty to 90% of thyroid cancers
re PTCs and almost half of those are clinically evident PTMCs.3,4
The increasing incidence of small thyroid cancers was suggested
o be caused by the use of sensitive screening imaging tools capable
f identify subclinical disease in a way that, in countries with access
o technology, 90% of incidental cases are due to low risk thyroid
ancer. Besides that, there is no evidence of any clinical impact
n mortality, so this increased incidence is probably an effect of
verdiagnosis, reﬂecting our capacity to detect occult and indolent
ancer.5–7
PTMCs usually have a benign behavior and do not affect patient
urvival.8 Considering their excellent prognosis and low mortality
ate, one would expect that PTMCs were an indolent disease.9 How-
ver, in some cases, PTMCs have an aggressive behavior leading to
oco-regional recurrence, distant metastasis and mortality.10
The predictive factors for this aggressively behavior have not
een completely recognized, but clinicopathological factors such
s age greater than 45 years, male gender, tumor size bigger than
 mm,  multifocality, lymph nodes metastasis (LNM) and extrathy-
oidal extension (ETE) have been reported as predictors of poor
rognosis.4,11 On the other side, many studies are trying to ﬁnd the
elationship between some molecular characteristics of PTMCs and
heir behavior. BRAF mutation, RET/PTC rearrangement, NAD(P)H
nd NRH polymorphisms, TERT mutation, and many molecular
arkers may  play a role in PTMC behavior.
The uncertainty of the risk associated to PTMCs is proba-
ly responsible for the controversial management of these small
umors. It is not always easy to deﬁne the best way to manage these
atients in terms of treatment and follow-up.
To estimate the prognosis and to ﬁnd a marker or a combina-
ion of markers able to stratify the clinical risk in PTMC became an
mportant issue due to the need of tools that may  assist in deﬁning
he best therapeutic approach for patients with this kind of cancer.
In this review, we analyzed the molecular biology behind PTMC
o contribute for the understanding of the inﬂuence of genetic
lterations, molecular pathways and other biomarkers in PTMC
ehavior, having as an ultimate goal the identiﬁcation of prognostic
arkers in this setting.ethods
The literature was retrieved using PubMed and aided by manual
earching. The terms papillary thyroid microcarcinoma were usedOpen  Access  sob  uma  licenc¸ a CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
as keywords connected by the Boolean operator AND. Inclusion
criteria were: published in English literature and during the last
10 years.
The query obtained through the database was: papillary
[All Fields] AND (“thyroid gland”[MeSH Terms] OR (“thyroid”[All
Fields] AND “gland”[All Fields]) OR “thyroid gland”[All Fields] OR
“thyroid”[All Fields] OR “thyroid (usp)”[MeSH Terms] OR (“thy-
roid”[All Fields] AND “(usp)”[All Fields]) OR “thyroid (usp)”[All
Fields]) AND microcarcinoma[All Fields] AND  english[Language]
AND (“2004/11/30”[CRDAT]: “2014/11/30”[CRDAT]) AND
(“2004/11/31”[PDAT]: “2014/11/31”[PDAT]) AND English[lang].
This research provided 410 potentially relevant articles. The
articles that did not seem focused on molecular biology of PTMCs
were excluded through title and/or abstract review. After that, 46
potentially relevant articles remained, which were evaluated in
detail. Forty-ﬁve of them were selected, and the remaining one
excluded.
Finally, automatic alert up to February 2015 provided one more
article eligible for this review and 13 more articles were also manu-
ally included through bibliographic references from review articles,
resulting in total of 59 articles.
Review
BRAFV600E mutation
B-type Raf kinase (BRAF), a serine/threonine-selective protein
kinase, is involved in the mitogen-activated protein kinase (MAPK)
pathway.12 This signaling pathway is involved in the regulation
of cell growth, division, and proliferation.13 When constitutively
activated, causes abnormal cell proliferation, adhesion, migration
and invasion, leading to carcinogenesis.8,12
BRAFV600E, the consequence of a unique thymine-to-adenine
transversion, represents more than 90% of all the mutations found
in the BRAF gene and is a very speciﬁc sign for PTC.12,14 Besides
enhancing the capacity of BRAF mutated cells to proliferate and
transform and the association with an increase in matrix metal-
loproteinases and desmoplastic stromal reaction, there are many
roles attributed to BRAFV600E, namely: up-regulation of tumor
promoting genes, down-regulation of tumor suppressor genes,
angiogenesis, promotion of tumor growth, tissue invasion and
extracellular matrix remodeling.15–18
The BRAFV600E mutation is the most common genetic alter-
ation in PTC and has been associated with poor prognostic factors.19
However, literature remains controversial in this question. With
regard to PTMC, the utility of BRAFV600E mutation, detected in
15.8–52% of PTMC cases, as a prognostic factor is unclear.13,14
Therefore, many efforts have been made to understand the role
of this mutation.
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Sedliarou et al. analyzed 46 PTMCs from 31 Russian and 15
apanese patients.20 Mutated BRAF was found in 13 cases (28.2%),
 in Russian (29.0%) and 4 in Japanese patients (26.6%). Presence of
he BRAF mutation did not signiﬁcantly correlate with any of the
valuated parameters, namely, gender, age at presentation, LNM
nd distant metastases.
Kim et al. detected BRAFV600E mutation in 31 of 60 Korean
atients (52%) with PTMCs.19 Despite no signiﬁcantly association
as found with prognostic factors like age, gender, tumor size,
ultifocality, ETE and staging, some trends were observed. Tumors
arboring BRAF mutation had higher probabilities of ETE, multifo-
ality and LNM. In that study, the four tumors with lateral neck node
etastases, including both patients with higher stages and the two
atients with cervical neck recurrence during the follow-up, were
RAFV600E positives.
Min  et al. analyzed the occurrence of the BRAFV600E mutation
n relation to LNM.4 They detected BRAFV600E mutation in 32 of
0 PTMC cases (53%) and its occurrence was not associated to any
linicopathological features including LNM.
Kwak et al. evaluated, in a retrospective study, the relationship
etween BRAF mutation and poor prognostic factors and ultra-
ound (US) features.13 The BRAFV600E mutation was  detected in
13 of 339 (62.8%) of PTMC cases and was signiﬁcantly associated
ith tumor size, ETE, and high TNM stage in PTMC, but it was  not
igniﬁcantly associated with any US features, although there was
n extremely strong trend toward the feature of marked hypoe-
hogenicity.
Lee et al. focused their attention in establishing the correla-
ion between BRAFV600E and PTMCs with aggressive behavior.
RAFV600E mutation was detected in 24 of 64 PTMC cases (37.5%)
nd a signiﬁcant association was observed with prognostic indica-
ors, namely, T3 and T4 stage, LNM and ETE.21
Basolo et al., through an analysis of a sample of 578 PTCMs,
howed a statistically signiﬁcant association between BRAFV600E,
resent in 39.4% of the cases, and age at diagnosis, absence of tumor
apsule, ETE, LNM and higher stages of disease.22 The mutation was
ot signiﬁcantly associated with multifocality.
Lin et al. analyzed the utility of BRAF mutation screening of ﬁne
eedle aspiration biopsy (FNAB) samples in predicting aggressive
haracteristics of PTMC.23 The BRAFV600E frequency in the PTMC
as 34% (21 of 61) and was signiﬁcantly associated with multifocal-
ty, ETE, lateral LNM, and advanced disease stages. Moreover, BRAF
utation was an independent predictive factor for lateral LNM.
Marchetti et al. did not ﬁnd a signiﬁcant relationship between
RAFV600E mutation, detected in 63 of 85 PTMCs (74%), and clinical
eatures as multifocal disease, ETE and LNM.24
Zhou et al. analyzed 100 patients with clinically unilateral PTMC
n order to investigate risk factors associated with occult con-
ralateral carcinoma with emphasis on BRAF mutation on FNAB
amples.25 Thirty-one in 100 patients (31%) were BRAF positive.
f the 20 patients identiﬁed with occult contralateral carcinoma
20%) preoperative BRAF mutation positive status was  found in 12
60%). The poorer outcome of bilateral PTC patients may  be in part
xplained by the high incidence of BRAFV600E mutation and the
act that bilateral PTC often arises from a single clone with con-
ordant BRAF status. Therefore they hypothesized and conﬁrmed
hat preoperative BRAF mutation is an independent predictive fac-
or for occult contralateral PTMC, suggesting that in these patients
 total thyroidectomy should be considered.
Kurtulmus et al. observed the BRAFV600E mutation in 19 of
4 Turkish patients with PTMC (29.7%) and found that LNM rate
igniﬁcantly increased when the mutation was present and also
hat mutation was more frequent in classic type.26 Multifocality
nd ETE did not signiﬁcantly differ according to BRAF status.
Rossi et al. evaluated a sample of 50 patients with PTMCs in
hich 35 had the BRAF mutation (70%) and found a signiﬁcantDiabetes Metab. 2016;11(2):287–295 289
association between BRAF mutation and bilateral disease and LNM,
but not with ETE.27
Zheng et al. analyzed the clinical characteristics and
BRAFV600E mutational status of 977 PTMCs in a Chinese pop-
ulation, 40.1% (392/977) were BRAFV600E positive.10 Their
results showed that BRAFV600E mutation was  signiﬁcantly
associated with ETE, LNM and male gender but not associated
with age, multifocality, TNM staging, and distant metastasis. Their
analysis also showed that tumor recurrence was  not associated
with BRAFV600E mutation.
Choi et al. observed the BRAFV600E mutation in 72 of 101 Korean
patients that underwent surgery for PTMC (71.3%) and did not
ﬁnd a signiﬁcant relationship between BRAFV600E mutation and
prognostic factors such as older age, gender, TNM staging, nodal
metastasis, multifocality, ETE, and distant metastasis.14
Mussazhanova et al. examined a small sample of 13 PTMCs of
which BRAFV600E mutation was  present in six cases (46%), and
found no signiﬁcant association between BRAFV600E and tumor
size, ETE or LNM.28
Walczyk et al. performed a retrospective analysis in a popu-
lation of 113 patients with PTMC with the least aggressive stage
(T1aN0/Nx).29 The BRAFV600E mutation was  found in 78 of the
113 patients (69.0%). During the 12 years of the study (2001–2012),
there was  no persistence, locoregional recurrence, lymph node or
distant metastases or mortality. In this study, there was no relation
between BRAF positive primary focus of PTMC and more aggressive
or recurrent disease.
Yang et al. in a retrospective study of 291 patients treated for
PTMC tried to identify predictive factors of central compartment
LNM, namely, BRAF mutation, among others. BRAFV600E mutation
was found in 124 of 291 (42.6%) patients and was independently
associated with central compartment LNM.30
Despite their mostly benign behavior, Piana et al. recently
reported three cases in which PTMCs, managed with optimal
treatment, recurred, metastasized and caused the death of the
patients.31 BRAF mutation was  absent in all cases, either at primary
tumor or in metastatic lesions.
In Table 1, we summarize the results of published studies on
BRAFV600E mutation in PTMC.
Other studies compared PTC with PTMC in order to understand
if PTMCs are an early stage of PTC or if they are different entities.
Park et al. compared a group of 278 PTMCs and 868 PTCs and
their results suggest that PTMC is not an indolent cancer and can
behave more aggressively like PTC.32 In that report, clinicopatho-
logical and prognostic features were not different between PTMC
and PTC and the frequency of BRAFV600E mutation was similar in
both groups, suggesting that their development biology may be the
same and that BRAF mutation may be important in the beginning
of PTC development.
Another study searched for some association between the BRAF
mutation and US features.15 A group of 688 patients with PTCs were
divided by BRAF mutation status and tumor size. There were no
differences between PTMC (514) and PTC (178) groups, in what
concerns US features. PTMCs with BRAF mutation were signiﬁcantly
larger than BRAF negative ones (8.0 ± 3.8 vs 7.1 ± 2.7 mm;  p = 0.004)
but no signiﬁcant differences in other US features, according to the
BRAF status, in either the PTMC or PTC group were found.
Soares et al. summarized the results of published studies on
BRAF. Comparing the results in PTMC with those observed in PTC, no
substantial differences were found in BRAF mutation prevalence.33
Others studies tried to establish a correlation between histology
of PTMC and BRAF status.It is important to notice the disparate frequency of the BRAF
mutation in the two major subtypes of PTMC. Through the analysis
of Table 1 it is clear that BRAF mutation is much more common in
the classical than in the follicular variant.
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Table 1
Summary of published studies of BRAF mutation in papillary thyroid microcarcinoma.
Study No. of
cases
Histologic variants, n (%) BRAFV600E
mutation, n
(%)
Histologic variants, n (%)
Classic Follicular Tall cell Sclerosing Warthin-like Others Classic Follicular Tall cell Sclerosing Warthin-
like
Others
Sedliarou et al.
(2004)20
46 29/46 (63)a 16/46 (35) – – – 1/46 (2) 13/46 (28)b 12/29 (41) 1/16 (6) – –  – 0/1 (0)
Kim  et al. (2005)19 60  60/60 (100) – – – – – 31/60 (52) 31/60 (52) – – –  – –
Trovisco  et al.
(2005)54
20  14/20 (70) 6/20 (30) – – – – 6/20 (30) 6/14 (43) 0/6 (0) – –  – –
Lin  et al. (2008)55 19 NR 4/19 (21) NR
Min  et al. (2008)4 60  NR 32/60 (53) NR
Kwak  et al. (2009)13 339 NR 213/339 (63) NR
Lee  et al. (2009)21 64 NR NR 4/64 (6) NR NR NR 24/64 (38) NR NR 2/4 (50) NR NR NR
Nasr  et al. (2009)56 5 NR 2/5 (40) NR
Basolo  et al.
(2010)22
581 NR 232/581
(40)c
NR
Lin  et al. (2010)23 61 NR 21/61 (34) NR
Park  et al. (2010)32 92 NR 62/92 (67) NR
Jung  et  al. (2012)57 721 666/721
(92)
51/721 (7) 2/721 (<0.01) – 2/721 (<0.01) – 576/721
(80)d
539/666
(81)
34/51 (67) 2/2 (100) –  1/2 (50) –
Lee  et al. (2012)58 275 NR 223/275 (81) NR
Marchetti  et al.
(2012)24
85 85/85 (100) – – – – – 63/85 (74) 63/85 (74) – – –  – –
Niemeier  et al.
(2012)34
51 NR 28/51 (55) NR
Zhou  et al. (2012)25 100 NR 31/100 (31) NR
Kurtulmus  et al.
(2012)26
64 53/64 (83) NR NR NR NR NR 19/64 (30) 19/53 (36) – – –  – –
Bernstein  et al.
(2013)16
53 26/53 (49) – 27/53 (51) – – – 45/53 (85) 20/26 (77) – 25/27 (93) –  – –
Piana  et al. (2013)31 3 1/3 (33) 2/3 (67) – – – – 0/3 (0) 0/1 (0) 0/2 (0) – –  – –
Rossi  et al. (2013)27 50  24/50 (48) 15/50 (30) 11/50 (22) – – – 35/50 (70) 21/24 (88) 3/15 (20) 11/11 (100) –  – –
Virk  et al. (2013)11 129 61/129 (47) 14/129 (11) 11/129 (9) 30/129
(23)e
3/129 (2) 10/129 (8)f 90/129 (70) 46/61 (75) 3/14 (21) 10/11 (90) 22/30 (73) 1/3 (33) 8/10 (80)
Zheng  et al. (2013)10 977 NR 392/977 (40) NR
Choi  et al. (2013)14 101 NR 72/101 (71) NR
Mussazhanova  et al.
(2013)28
13 8/13 (62) 5/13 (38) – – – – 6/13 (46) 6/8 (75) 0/5 (0) – –  – –
Park  et al. (2014)15 514 NR 335/514 (65) NR
Walczyk  et al.
(2014)29
113 92/113
(81)g
12/113 (11) – – – 9/113 (8)h 78/113 (69) 66/92 (71) 8/12 (67) – –  – 4/9 (44)
Yang  et al. (2014)30 291 NR 124/291 (43) NR
Total  4887 1119/1357
(82)
121/1095 (11) 55/1017 (5) 30/129 (23) 5/850 (0.6) 20/288 (7) 2757/4887
(56)
829/1119
(74)
49/121 (40) 50/55 (91) 22/30 (73) 2/5 (40) 12/20 (60)
Abbreviation: NR, not reported.
a Includes papillary (n = 11), mixed (papillary/follicular) (n = 8) and mixed solid/trabecular structures (n = 10) subtypes.
b In all cases, BRAF mutation is the BRAFT1796A transversion.
c Three cases with BRAFK601E mutation included.
d Three cases with rare BRAF mutations included.
e Includes subcapsular sclerosing (n = 17) and occult sclerosing (n = 13) subtypes.
f Includes oncocytic (n = 1) subtype and nine unclassiﬁed PTMCs.
g Includes papillary (n = 91) and mixed (papillary/follicular) (n = 1).
h Includes oxyphilic (n = 2) subtype and seven unclassiﬁed PTMCs.
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gene expression is an indicator of a worse prognosis raising the
question of its importance in PTMC.40B. Castro, E. Rodrigues / Rev Port Endo
The prevalence of the BRAFV600E mutation is reported to be
s high as 80–100% in tall cell variants, but what we know about
his PTMC subtype is not much.16 In a study from 2013, it was
emonstrated for the ﬁrst time that, despite the small size, these
icrocarcinomas are signiﬁcantly associated with ETE and more
dvanced stage at presentation, and they are more frequently
ssociated with multifocality, lymphovascular invasion, LNM and
RAFV600E mutation when compared to classic PTMC.16
Virk et al. concluded that PTMC has an idiosyncratic morphology
n relation with BRAF mutation status.11 Mutated microcarcino-
as  presented signiﬁcantly higher prevalence of inﬁltrative tumor
orders, presence of stromal desmoplasia, ﬁbrosis and/or sclero-
is, classic nuclear characteristics of papillary carcinoma and cystic
hange. Tumors harboring the mutation were also signiﬁcantly
ssociated with LNM particularly lateral cervical LNM, and ETE.
Niemeier et al. projected a risk-stratifying model for patients
ith PTMC.34 A combined molecular-pathology (MP) score was
roposed based on BRAF mutational status of the tumor more three
istopathological features – multifocality/intraglandular tumor
pread, tumor ﬁbrosis and superﬁcial tumor location in the gland.
hey offer a very simple score that can be helpful in the evalua-
ion of cancer aggressiveness. The combined MP  score allows to
tratify tumors in one of three categories of probability of LNM
r tumor recurrence (low risk: 0%, moderate-risk: 20%, and high-
isk: 60%). This score proved to be better than either molecular or
istopathologic evaluation alone.
The recent study done by Biase et al. tried to clarify the distri-
ution of BRAFV600E and, by using a sample of 85 BRAF positives
TCs, it was able to identify three groups of tumors by the distribu-
ion of mutated cells: greater than 80% in 43.5%, 30–80% in 45.9%,
nd less than 30% in 10.6%.35 The statistical association between
TMC and the tumor group featuring less than 30% BRAFV600E
utated cells highlights the possibility of considering PTMCs as
n early stage of PTCs. There was a trend for larger tumors to have
 higher proportion of BRAF mutated cells supporting the hypoth-
sis that BRAF mutation promotes tumor growth and, in the cases
ith a higher proportion of mutated cells, BRAFV600E may  be the
ounding genetic alteration.
Based on previous reports that BRAF mutation could be detected
eripherally in the serum or blood of PTCs patients, Kwak et al.
ried to establish if it is worth to detect the peripheral BRAFV600E
utation in order to use it as serum tumor marker.12 For that,
hey obtained 94 serum samples from patients with PTC harbor-
ng BRAFV600E mutation in the tumor itself, of which 67 patients
71.3%) had PTMC. Unfortunately, they were incapable to identify
eripheral BRAFV600E mutations with real time PCR. So, until now,
ven if we consider to use BRAF mutation to help on the manage-
ent of PTMCs, we only have an invasive procedure such as FNAB
o identify this genetic alteration.
We must emphasize a recently published meta-analysis by Li
t al. performed in order to ascertain the relationship between
RAFV600E mutation and the clinicopathological features of
TMC.36 Nineteen studies comprising 3437 patients were included
nd 47.48% of these patients had BRAFV600E mutation, with no
igniﬁcant difference according to patient gender or age. In com-
arison with the wild-type, BRAFV600E mutation was  associated
ith tumor multifocality, ETE, LNM, and advanced stage of PTMC.
o, the ﬁndings from this meta-analysis clearly demonstrate that
TMCs harboring BRAFV600E mutation have a greater tendency
or increased aggressiveness. However, a subgroup analyses done
ccording to the country of the study revealed that BRAFV600E
utation is not signiﬁcantly correlated with aggressive clinico-
athological behaviors of PTMC in patients from Korea, where the
utation is highly prevalent. Therefore, BRAF mutation may  haveelatively restricted prognostic value in areas where BRAFV600E
utation has an extremely high prevalence.Diabetes Metab. 2016;11(2):287–295 291
RET/PTC rearrangement
The RET/PTC rearrangement, the ﬁrst genetic alteration assigned
to PTC, also triggers MAPK pathway and was  considered to have
some prognostic value.33 However, it has been reported that
RET/PTC rearrangement, present in PTMC in up to 52% of the
cases, is a ﬁnding that does not seem to be related to cancer
aggressiveness.18 Nevertheless, the great prevalence of RET/PTC
translocations reported in PTMCs suggests that the activation of
this oncogene has a responsibility in a premature stage of PTMC.8
The results of the published studies on RET/PTC were summa-
rized in a recent report.33 Comparing the results in PTMC with those
observed in PTC, no substantial differences were found in RET/PTC
rearrangement prevalence. On the same report they concluded that
this rearrangement, as we  said, highly prevalent in PTMC, is rare in
less-differentiated thyroid cancers. This is consistent with previous
reports conﬁrming the weakness of RET/PTC in contrast with other
oncogenes, and could explain why most PTMCs do not grow, or even
if they do, they do not evolve to poorly differentiated or undifferen-
tiated carcinomas with a more hostile behavior, despite their ability
of regional metastization. Tumors with RET/PTC rearrangement are
more frequently, small, slow growing and predominantly with pap-
illary architecture.
NAD(P)H and NRH polymorphisms
NAD(P)H Quinone Oxidoreductase 1 (NQO1) and NRH Quinone
Oxidoreductase 2 (NQO2) seem to protect against oxidative stress
and its carcinogenic effect. Polymorphisms on these enzymes have
been suggested as predictive factors for cancer susceptibility and
development.37
Lee et al. investigated the link between NQO1/NQO2 genotype
and clinicopathological characteristics of PTMC, concluding that
NQO1 and NQO2 polymorphisms are associated with aggressive
phenotypes.37 The homozygous genotype of the polymorphic vari-
ant of NQO2 could be a prognostic marker because of the signiﬁcant
relationship with an increased risk of LNM. Also, PTMC with poly-
morphic NQO1 frequently exhibited ETE when compared to PTMC
NQO1 wild-type. It was also investigated the response of Nrf2, a
marker against oxidative stress. PTMC harboring the polymorphic
variants showed higher Nrf2 expression, signifying that the lack of
normal NQO1 and NQO2 might cause strong oxidative reaction.
TERT mutation
Mutations in the promoter region of telomerase reverse
transcriptase (TERT), which can lead to persistent telomere
lengthening, are indicators of thyroid tumors aggressiveness
being intensely associated with increased risk of recurrence and
mortality.6
In a retrospective study, TERT mutations were associated with
a high risk of disease speciﬁc mortality in patients with PTC com-
pared with those without the mutation. In what concerns to PTMCs,
no TERT mutations were described in tumors smaller than 1 cm.38
In another study, with a very small series to allow a grounded
conclusion, TERT mutations were observed in 8% of PTC and in 0%
of PTMC cases.33,39
Other molecular pathways in PTMC
P53. The p53 gene, which encodes a nuclear tumor suppressor pro-
tein, is involved in the cell cycle being capable of inhibiting cell
proliferation and transformation.9,40 It has been described that p53Recent ﬁndings demonstrated no association between p53
expression and poor prognostic in PTMC.9 Probably because they
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re an early cancer, whereas p53 is usually a late genetic event
sually associated with aggressive tumors and particularly to less
ifferentiated/undifferentiated thyroid tumors.
In 2006, Corapcioglu et al. studied a total of 44 patients with
TMCs.40 Of them, 29 had preparations viable to stain for p53
xpression. They found p53 positivity in 34.5% and this was  not sig-
iﬁcantly correlated with gender, age, LNM, multifocality, capsular
nvasion, histological type, tumor location or size.
In 2007, Lim et al. evaluated the histopathological and clinical
haracteristics of 217 Korean patients with PTMC and P53 immuno-
istochemical staining was performed for 87 specimens.9 The p53
xpression was not associated with any known prognostic factors.
Also, in the three cases with fatal outcome, mentioned above,
here were no evidences of p53 nuclear accumulation.31
A recent study tried to ﬁnd out whether the expression of some
olecules associated with the biological behavior of PTMC differed
etween patients with ETE and no ETE.41 In that context, immuno-
istochemical staining of p53 did not differ between either groups.
27. Another tumor suppressor gene is p27, important in cell cycle
egulation as an anti-cell cycle cyclin.8,32
In 2008, Min  et al. analyzed the p27 expression in relation
o LNM.4 Loss of p27, associated with thyroid cancer and previ-
usly reported as a predictive factor for recurrence and LNM, was
bserved in 125 of 198 PTMCs (63%) without any association with
NM.4,32
Other study, comparing PTC and PTMC, studied the expression
f some molecular markers.32 The immunohistochemical analysis
evealed no different expression pattern of p27 in relation to the
umor size.
OX-2, EGFR and ki-67. The enzyme cyclooxygenase-2 (COX-2),
hich is responsible for the formation of prostaglandins from
rachidonic acid, is induced by several growth factors, cytokines
nd oncogenes.9 It is frequently expressed in PTC and in some
eports is more frequent in PTMC than in PTC. It has been suggested
hat it might serve as a useful diagnostic as well as a prognostic
olecular marker for PTC.
Epidermal growth factor receptor (EGFR) has been reported as
n independent prognostic factor for thyroid cancer.9 Also, its over-
xpression has been related to cancer recurrence. However, this has
een shown mainly for PTC larger than 1 cm.9,41
The ki-67 antigen is a marker of proliferative activity and seems
o relate with worse clinical outcome.9 It was also reported that its
xpression increases signiﬁcantly with age explaining the poorer
rognosis in older patients.
In the same 2007 report from Lim, mentioned above, immuno-
istochemical staining of COX-2, EGFR and ki-67 for 87 specimens
as performed.9
After evaluating the expression of those molecular markers they
roved that the absence of EGFR expression was associated with
TE and LNM while the absence of COX-2 expression was correlated
ith bilaterality and multifocality. Moreover, ETE showed a trend of
ositive relation to the absence of EGFR expression, although not
tatistically signiﬁcant. The ki-67 expression was very low, sug-
esting a slowly progressive disease and was not associated with
ecognized prognostic factors.
EGFR may  still control the growth in small tumors explaining
hy higher EGFR expression was inversely correlated with ETE and
NM.9 Other study revealed no difference in the expression of EGFR
attern in relation to ETE.41In a recent study, the expression of ki-67 was assessed in PTMCs
umors and LNMs.42 The ki-67 index was generally low in both
rimary PTMC and in the metastasis and was not associated signif-
cantly with clinicopathological characteristics. No difference wasDiabetes Metab. 2016;11(2):287–295
found in ki-67 index at the invasive front compared to the center
of the tumor.
S1004. S100A4 is a member of the S100 family of calcium-binding
proteins involved in tumor progression, metastasis and angiogen-
esis promotion.8 It has been shown to be a prognostic marker in
various human cancers.4,8
In a series of 198 PTMCs, S100A4, expressed in 69% of the cases
predicted LNM.4 Moreover, expression of S100A4, particularly its
strong expression in the invasive front of the tumors, was  signiﬁ-
cantly and independently associated with lateral node metastasis
and macrometastasis, suggesting that its overexpression is associ-
ated with invasion and nodal metastasization of PTMCs. Expression
of S100A4 may  be useful for prediction of metastatic potential of
PTMCs.
Cyclin D1. Cyclin D1, which activates cyclin-dependent kinases,
may  participate in cancer progression, but we still are in face of
inconclusive results.32 Overexpression of cyclin D1 on immunohis-
tochemistry is strongly associated with LNM in PTMC.43 However,
similar results were observed in patients without LNM.18,43
Through the immunohistochemical analysis of 35 cases of PTMC,
Lantsov et al. found a signiﬁcant association between cyclin D1
expression and tumor size and LNM. The level of cyclin D1 was
signiﬁcantly lower in PTMC < 5 mm than in PTMC > 5 mm or PTC.
All PTMC cases with LNM were > 5 mm  and 80% showed a high
level of cyclin D1 overexpression. Thus, cyclin D1 may  be up-
regulated early in thyroid carcinogenesis promoting tumor growth
and metastatic process.44
Antonaci et al. evaluated cyclin D1 expression in 31 PTCs and
36 PTMCs.45 Staining for cyclin D1 was observed in all PTCs and in
61.1% of PTMCs. Moreover, they showed that cyclin D1 overexpress-
ion is correlated with the expression of survivin, an anti-apoptotic
protein that also intervenes in cell proliferation. Cyclin D1 and sur-
vivin over-expression are presumably early events, since a high
percentage of PTMCs showed the same proﬁle as PTCs. They also
found cyclin D1 is over-expressed in LNM and emphasize that the
higher expression of both cyclin D1 and survivin in tumor tissues
than in normal tissues could be useful to detect single cell trans-
formation in FNAB samples facilitating early diagnosis.
Also in the study by Min  et al., in a cohort of 198 PTMCs, the
expression of cyclin D1, with intense nuclear staining in 60%, pre-
dicted LNM.4 Cyclin D1 expression was signiﬁcantly higher in the
older age group and larger tumors and lower in follicular variants.
Londero et al. studied 131 PTMCs in order to evaluate if the
expression of cyclin D1 could predict metastization.46 Forty-three
of PTMCs (33%) had regional or distant metastases. Cyclin D1
median expression was  signiﬁcantly higher in patients with metas-
tases in comparison to those without, indicating a correlation with
tumor aggressiveness. Nonetheless, both groups showed wide vari-
ation in expression, which disqualify the marker as a discriminator
for metastasis detection.
Park et al. found no differences between PTC larger than 1 cm
and PTMC in cyclin D1 expression.32
Immunohistochemical analysis for cyclin D1 was  also per-
formed in the three cases mentioned previously.31 Cyclin D1 was
expressed in both primary PTMC and metastatic cells. Findings in
these three cases suggests that cell cycle deregulation is relevant
in the progression of PTMC and supports its potential as a marker
to predict LNM.31,47
Galectin-3. Overexpression of galectin-3 revealed to be a reliable
marker for thyroid cancer. This molecule is involved in interac-
tions between cells and between them and the extracellular matrix.
Galectin-3 also controls cell growth, malignant transformation and
metastatic process, allowing resistance to apoptosis.32
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Cvejic et al., in 2005, analyzed galectin-3 expression in 63 cases
f PTMC, concluding that its presence in incidentally found micro-
arcinomas has no relation with tumor growth or aggressiveness.48
mmunohistochemical reactivity was evident in 51 cases (80.9%).
nly three cases involved LNM, and they were galectin-3 positive.
he other 48 cases expressed galectin-3, without LNM, suggesting
hat galectin-3 expression, itself, has not a metastatic potential.
Other studies evaluated whether galectin-3 expression in PTMC
ould be a marker of LNM but the results showed no signiﬁcant
elation.18
In Londeros’s study, it was also evaluated if galectin-3 could
redict metastization but its expression showed no signiﬁcant cor-
elation with PTMC metastases.46
A recent report from Kim41 showed no difference in the expres-
ion of galectin-3 between patients with and without ETE.
MWK,  CK-19 and HBME-1. High molecular weight keratin
HMWK) and cytokeratin-19 (CK-19) are useful markers for
ifferentiating papillary carcinomas from benign lesions and
re sensitive markers for PTCs.32 Hector Battifora mesothelial-1
HBME-1) is helpful in the diagnosis of follicular cell-derived thy-
oid tumors.32 In 2010, Park et al. in a comparison between PTC and
TMC explored the expression of these three molecular markers.32
he immunohistochemical analysis exhibited no different expres-
ion pattern according to the tumor size suggesting that larger PTCs
nd PTMCs have similar molecular characteristics.
GF and c-MET. The hepatocyte growth factor (HGF)/c-Met path-
ay has been related with tumor invasion in various cancers and
GF and c-Met expression are low and rare in benign lesions
hen compared with their high levels in thyroid cancer.49 Vascular
ndothelial growth factor (VEGF) overexpression is involved in cell
roliferation, migration and survival and was found to be increased
n thyroid metastasis when compared with the expression in pri-
ary lesions.
A recent report, from Koo et al., was the ﬁrst that tried to evalu-
te the signiﬁcance of HGF and c-Met as a predictive marker for
ubclinical LNM (SLNM) in PTMC.49 They analyzed the associa-
ion between HGF and c-Met expression and SLNM in 113 patients
ith clinically identiﬁed PTMCs. Positive immunohistochemical
GF and c-Met staining was found in 107 (95%) and 103 (91%)
ases, respectively, and it was strongly correlated with SLNM. The
n vitro studies that they performed demonstrated that HGF stim-
lation and constitutive c-Met activation increases the migration
nd invasiveness of cancer cells by rising VEGF-A expression.
embrane mucins. Membrane mucins include a heterogeneous
amily of glycoproteins that are characteristic of epithelial cells and
ave a protective function, behaving like a barrier against infec-
ion and being responsible for lubricating epithelial cell surfaces.
owever, their protective function can be harnessed by neoplastic
ells to defend them against immunological mechanisms. They may
erve, as well, as cell surface receptors directing signals, conducting
o responses such as differentiation, proliferation or apoptosis and,
nce again, cancer cells might use mucins to protect themselves
rom hostile environment and to adapt the local conditions during
nvasion.50
MUC1 expression was also analyzed in Min’s study and was
etected in 96 cases (49%) and did not predict LNM, but was asso-
iated with larger tumor size.4In 2011, Nam and colleagues evaluated the expression levels
f MUC4 and MUC15 and their prognostic meaning in PTC.50 They
ot only concluded that those mucins were overexpressed in PTC,
ut also observed that high MUC4 expression was  signiﬁcantlyDiabetes Metab. 2016;11(2):287–295 293
correlated with small tumors and PTMC subtype, so MUC4 may
have a relevant intervention in early oncogenesis.
Cell adhesion molecules. Kim et al. performed an oligonucleotide
microarray analysis of PTMCs to disclose their gene expression pro-
ﬁles and to compare the results with those of PTCs.3 Most of the
commonly up-regulated and down-regulated genes in PTMCs were
functionally associated cell adhesion and cell-mediated immunity.
In the comparative analysis of gene expression proﬁles of PTMCs
and PTCs, no signiﬁcant difference was found in a way that they
cannot be distinguished by gene expression proﬁles.
Three others studies focused on the relationship of speciﬁc
adhesion molecules, such as epithelial cell adhesion molecule
(EpCAM) and E-cadherin, and clinicopathological factors of
PTMC.42,51,52
Epithelial cell adhesion molecule (EpCAM) has an intracellular
domain (Ep-ICD), a transmembrane domain and an extracellular
domain (EpEx). EpCAM intervenes in a variety of cell processes
including proliferation, adhesion, differentiation, cell cycle regu-
lation and is involved in cancer signaling.
Kunavizarut et al., hypothesized that accumulation of Ep-ICD
and loss of EpEx could be useful for distinguishing metastatic PTMC,
since it was  previously reported that Ep-ICD accumulation and loss
of EpEx correlated with a worse prognosis in thyroid malignancy.52
Tissue samples from 36 patients were stained for Ep-ICD and
EpEx by immunohistochemistry. Cytoplasmic and nuclear Ep-ICD
expression and loss of membranous EpEx showed to be positively
correlated with metastasis in PTMC patients. An index of aggres-
siveness, Ep-ICD subcellular localization index (ESLI), was  deﬁned
as the sum of the immunohistochemistry scores for accumulation
of Ep-ICD and loss of EpEx. ESLI was  signiﬁcantly associated with
LNM in PTMC and therefore may  be useful in identifying metastatic
potential of these tumors.
The loss of E-cadherin occurs in the process of cancer cell trans-
formation when they change their characteristics from an epithelial
to a mesenchymal-like type.42 E-cadherin is frequently expressed
in differentiated thyroid cancer and loss of its expression was
reported to be an independent prognostic factor for these cancers.
Nakamura et al. evaluated 93 PTMCs patients and 57 LNM for E-
cadherin expression.42 From these, 73 tumors (78.5%) and 49 LNM
(86%) were immunohistochemically positive. In comparison to the
center of the tumor, E-cadherin expression was signiﬁcantly less
common at the invasive front. Tumors that had lost E-cadherin
expression at the invasive front frequently presented with LNM.
Small tumors (≤5 mm)  expressed E-cadherin signiﬁcantly more
frequently when compared with the larger ones. Observing that
the tumors which lost E-cadherin expression at the invasive front,
commonly presented with LNM suggests that, even in small PTMCs,
the process of cancer cell dissemination has already begun.
Batistatou et al. examined the expression of dysadherin, an
anti-cell–cell adhesion glycoprotein, in PTMC, to relate it with E-
cadherin expression and ﬁnd out the differences with PTC.51 A
statistically signiﬁcant difference in dysadherin and E-cadherin
expression between PTC and PTMC and a negative correlation
between E-cadherin and dysadherin expression were observed. E-
cadherin expression was retained in about half of the PTMCs and
was low in only 10% of them, whereas reduction of E-cadherin
expression was  signiﬁcantly higher in PTCs. The indolent course of
PTMC may  be due, at least in part, to the absence of high dysadherin
expression in consequence of the maintenance of the E-cadherin,
which prevents tumor cells from separating easily from each other
and metastasize. Increased dysadherin expression is, maybe, one
of the mechanisms responsible for E-cadherin downregulation in
thyroid papillary cancer.
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onclusion
The approach of PTMCs remains controversial due to discrepant
atural history of these apparently benevolent small tumors. Here-
pon, it is of great importance to distinguish between nonincidental
TMC – clinically recognized PTMC – and incidental PTMC – asymp-
omatic PTMC found after surgery or during US performed for other
otives. These two groups appear to be biologically distinct. From
ne side we have indolent tumors with nearly no potential for pro-
ression and, in the other side, tumors with the predisposition for a
ore aggressive course with clinical features comparable to those
f conventional PTC.
In addition to clinical and histopathological factors, biomarkers
re urgently required to assist in identiﬁcation of the minority of
atients that belong to the aggressive group. Unfortunately, until
ow, there is no biological marker that deﬁnes prognosis with cer-
ainty.
Despite the results not being entirely consistent, BRAFV600E
s associated, in most reports, with aggressive clinicopathologi-
al characteristics such as tumor size, male gender, LNM, ETE,
dvanced TNM stages, multifocality and bilaterality, being highly
revalent in the tall cell variant.
Nevertheless, one should look critically to those associations
ecause, ultimately, we cannot forget how prevalent this mutation
s in PTMCs and, by contrast, how low is the mortality associated
o this malignancy.
It is not wrong if we say that BRAF status analysis can improve
he diagnostic accuracy of preoperative thyroid lesions. As sug-
ested by Xing, considering the prevalence of BRAF mutation in
TMC around 30%, it appears practicable to treat more aggres-
ively (ex. total thyroidectomy vs lobectomy) the one-third of PTMC
atients that are positive for BRAF mutation on a FNAB sample and
ight have a worse prognosis.17 The remaining cases, the ones neg-
tive for BRAF mutation, could be managed more conservatively, if
o other factors indicated other approach.
In a recent review, the utility of BRAF testing in the management
f PTC was equated; unfortunately, with regard to PTMCs, no con-
lusion was reached.53 On the other side, the MP score proposed
y Niemeier seems an interesting tool for patients with PTMC,
lthough it is useless if we want to stratify risk before the surgical
pproach.
Singly, all genetic alterations, even BRAFV600E mutation, and
iomarkers have, yet, little potential to overcome the barrier
etween the laboratory and the clinical practice. The RET/PTC
earrangement does not have value in predicting a poor outcome;
n the contrary, NQO1 and NQO2 polymorphisms could be used
s prognostic markers because of their relation with invasiveness.
ERT mutation was not found in PTMCs. The tumor suppressor
enes p53 and p27 are not helpful. The expression of COX-2 and
GFR may  play a role in prognosis by their association with ETE,
NM, multifocality and bilaterality. S100A4 immunohistochem-
stry seems to be valuable for predicting metastatic potential.
yclin D1 may  predict LNM, but results are inconclusive. Galectin-
, HMWK,  CK-19 and HBME-1 are not of great utility since their
xpression is similar in PTMCs and PTCs. HGF and c-MET expression
ere identiﬁed as signiﬁcant factors for SLNM. From the existing
ata about membrane mucins we cannot achieve many conclu-
ions. Cell adhesion molecules, especially EpCAM and E-cadherin,
eed to be studied in more detail in order to clarify their possible
ontribution in the metastatic process.
If a variety of molecular markers were evaluated many patients
ould be accordingly stratiﬁed for management. Thus, further stud-
es are needed in order to try a combination of several markers
or the purpose of increasing the probability of identifying the
ases with more aggressive behavior and thus allow better and
argeted treatment. Long-term randomized prospective studies are
1
1Diabetes Metab. 2016;11(2):287–295
required as well as more information in what concerns to molecular
ﬁndings.
In regards to clinicopathological features with prognostic value,
we should remember the dichotomy inherent to the age at diag-
nosis. Although older age at diagnosis has been recognized as an
element suggesting worse prognostic, it has been shown by Ito et al.
that young age is an independent predictor of PTMC progression.59
Therefore, old patients with subclinical low-risk PTMC may  be the
best candidates for observation. Although PTMC in young patients
may  be more progressive than in older ones, it appears that surgery
remains a viable option even after progression of subclinical PTMC
to clinical disease, without compromising the outcome.
Several questions about the genetics events associated to PTMC
remain unanswered. The main interrogations are the correlation
between pathogenesis and clinical outcome as well as the best way
to stratify clinically relevant subtypes of PTMC.
Determining a biological signature able to predict tumor aggres-
siveness would be a major discovery with enormous clinical
relevance that, ultimately, could prevent unnecessary and aggres-
sive treatment because of such a small tumor as a PTMC.
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